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Background: Retinitis pigmentosa is a heterogeneous group of inherited neurodegenerative retinal disorders
characterized by a progressive peripheral vision loss and night vision difficulties, subsequently leading to central
vision impairment. Chronic microglia activation is associated with various neurodegenerative diseases including
retinitis pigmentosa. The objective of this study was to quantify microglia activation in the retina of P23H rats, an
animal model of retinitis pigmentosa, and to evaluate the therapeutic effects of TUDCA (tauroursodeoxycholic acid),
which has been described as a neuroprotective compound.
Methods: For this study, homozygous P23H line 3 and Sprague-Dawley (SD) rats were injected weekly with TUDCA
(500 mg/kg, ip) or vehicle (saline) from 20 days to 4 months old. Vertical retinal sections and whole-mount retinas
were immunostained for specific markers of microglial cells (anti-CD11b, anti-Iba1 and anti-MHC-II). Microglial cell
morphology was analyzed and the number of retinal microglial was quantified.
Results: Microglial cells in the SD rat retinas were arranged in regular mosaics homogenously distributed within
the plexiform and ganglion cell layers. In the P23H rat retina, microglial cells increased in number in all layers
compared with control SD rat retinas, preserving the regular mosaic distribution. In addition, a large number of
amoeboid CD11b-positive cells were observed in the P23H rat retina, even in the subretinal space. Retinas of
TUDCA-treated P23H animals exhibited lower microglial cell number in all layers and absence of microglial cells
in the subretinal space.
Conclusions: These results report novel TUDCA anti-inflammatory actions, with potential therapeutic implications
for neurodegenerative diseases, including retinitis pigmentosa.
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Retinitis pigmentosa (RP) is a type of hereditary retinal
degeneration with high levels of clinical and genetic het-
erogeneity. This neurodegenerative retinal disorder is
characterized by a primary degeneration of the photo-
receptor rods causing peripheral vision loss and night
blindness. With the progression of the disease only the
cone cells of the fovea remain functional, leading to a
classical tunnel vision. In the end stage of the disease
with the dysfunction of all cone cells, the central visual
field degenerates and leads to a complete blindness. It is
currently known that more than 100 different mutations* Correspondence: cuenca@ua.es
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unless otherwise stated.in the rhodopsin-encoding gene (RHO) are related with
30 to 40% of autosomal dominant cases. The Pro-23-His
mutation is the most prevalent cause of RP [1], being
the genetic cause of about 15% of autosomal dominant
RP cases in the United States [2]. It is currently known
that the P23H mutation causes misfolding and retention
of rhodopsin in the endoplasmic reticulum [3]. Others
studies suggest that the mechanism of RP involves cellular
stress, inflammatory response, retinal remodeling, and the
final common pathway of programmed photoreceptor
cell death or apoptosis [4-6]. Similar mechanisms were
involved in other retinal degenerations like glaucoma,
diabetic retinopathy or macular degeneration [6].
Microglial cells act as the resident immune cells of the
central nervous system (CNS), including the retina, play-
ing the role of primary mediators of inflammation. In thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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morphology with a small, round soma, and various
branching processes and play critical functions in
axonal growth, synaptic remodeling and neuronal sur-
vival via phagocytosis of cellular debris and relief of a
variety of cell signaling factors [7,8]. In response to
negative stimulus, tissue injury or free radicals, micro-
glial cells assume a reactive state, characterized by a
shortening and widening of microglial processes [9].
These reactive microglial cells can progress into phago-
cytic microglial cells. In this amoeboid form, microglial
cells lack cellular processes and perform characteristic
macrophage functions. Activated microglial cells have
been observed in mouse models of autosomal recessive
RP [10,11], in rds mice [12] and in rat models of inherited
retinal degeneration, including Royal College of Surgeons
rats [13].
Activated microglial cells are able to generate trophic
biomolecules, glutamate transporters and antioxidants
that promote the correct neuronal functioning. But, like-
wise, activated microglial cells are capable of producing
potentially neurotoxic substances such as nitric oxide
(NO) and pro-inflammatory cytokines (IL-1α, IL-1β, TNF-α,
IFN-γ, IL-6, and so on) that are involved in neurological
diseases and CNS disturbances, like infections or chemical
damage and aging [14-17].
In retinal neurodegenerative diseases, chronic micro-
glial activation and neuroinflammation are common
phenomena. In RP, the primary death of rod photorecep-
tors triggers the activation of microglial cells and their
migration to the outer retina to eliminate cellular debris.
It has been proposed that these activated microglial cells
may release cytotoxic factors such as NO that kills adja-
cent photoreceptors, including cones [18]. In age-related
macular degeneration, previous studies show that micro-
glial cells become pathogenic with age, causing a chronic
activation that will influence the health of retinal tissue
[19,20]. Microglial cells also play a critical role in the pro-
gression of glaucoma. Many studies show that the number,
morphology, distribution and antigen-presenting activity
of microglial cells change in glaucomatous eyes highlight-
ing their importance in the pathological process [21-23].
In experimental models of diabetic retinopathy, microglial
cells also appear altered suggesting that the activation
process is underway. However, it is actually unknown
what degree of this activation is due to resident microglial
cells of the retina or to circulating monocytic cells [24].
Due to this duality, the function(s) performed by micro-
glia in regulation of injured neurons remain uncertain.
Numerous studies suggest that microglial activation is
harmful for neuronal survival, showing that the inhibition
of microglial activation and cytokine secretion causes a re-
duction of neuronal loss [25,26]. However, other research
makes evident the neuroprotective effect of microglialactivation [27,28]. Some research support that the trophic
and toxic effectors in microglia are controlled differen-
tially depending on the severity of neuronal lesion [29].
Under pathological conditions, microglial cells of the
retina are subjected to various kinds of endogenous and
exogenous signals. These stimuli trigger local proliferation
and changes in shape and morphology. Also, microglial
cells alter their location in the retinal tissue, cytokine re-
lease pattern and expression of surface molecular markers.
These characteristic immunological reactions and the
absence/failure of the self-regulation engine may lead
to an increase of retinal damage and pro-apoptotic
events [10,18,30].
In this study, we address the hypothesis that the
neuroprotective compound, tauroursodeoxycholic acid
(TUDCA), is able to prevent microglial activation,
modify its expression pattern and delay the photoreceptor
cells loss in an animal model of RP. We have employed in
our study, P23H and Sprague-Dawley (SD) rats to assess
the therapeutic potential of TUDCA on photoreceptor
degeneration and functional activity of the retina in these
animal groups.Methods
Animals
Homozygous P23H line 3 rats, obtained from Matthew
LaVail [31], were used in this study as a model of RP.
Age-matched wild-type SD rats (Harlan, IN, USA) were
used as control. All animals were housed in cages under
controlled photoperiod (12 hours light/12 hours dark),
temperature (23°C ±1°C) and humidity (55 to 60%). Food
and water were available ad libitum. All animals were
handled in accordance with current regulations for the
use of laboratory animals (NIH, ARVO and European
Directive 2010/63/UE) in order to minimize animal suf-
fering and limit the numbers used for the experiments.
The study had the approval of the Research Ethics
Committee of the University of Alicante.TUDCA treatment
TUDCA, purchased from Calbiochem (Gibbstown, NJ,
USA), was dissolved in physiological saline (0.9% NaCl)
just before administration by using an ultrasonic bath to
avoid bubble formation. TUDCA was administered weekly
to P23H line 3 rats (n = 6) at 500 mg/kg (intraperitoneally,
ip) from P (postnatal day) 20 to P120, when these animals
can be considered to have undergone extensive retinal de-
generation [31-34]. Untreated P23H rats (n = 6) received
the same volume of saline at the same time points. In
order to adjust the amount of TUDCA and vehicle admin-
istered, the animal body weight was measured before each
drug injection. Likewise, SD rats (n = 4) received a weekly
injection of saline according to their weight.
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Histological studies of the retinas were performed at
P120. Cryostat vertical sections and retinal whole-
mounts were obtained and processed for immunola-
beling following well established procedures [35-38].
Animals were sacrificed in the morning by administration
of a lethal dose of pentobarbital. After marking the dorsal
margin of the limbus with a suture, eyes were enucleated
and fixed in 4% (w/v) paraformaldehyde during 1 hour at
room temperature (RT). After being washed in 0.1 M
phosphate buffer pH 7.4 (PB), eyes were cryoprotected
sequentially in 15, 20 and 30% sucrose. The cornea, lens
and vitreous body were removed, and the eyecups were
processed for vertical sections and whole-mounts.
For whole-mounts immunohistochemistry we utilized
immunoperoxidase labeling. After fixation, retinas were
dissected out from choroid and flat-mounted on a
nitrocellulose filter, with the photoreceptor layer side
up. Endogenous peroxidase activity was suppressed by
immersion in 1% H2O2 (Sigma, St. Louis, MO, USA) in
PB (10 minutes, RT). In order to break aldehyde bonds
and enhance the permeability of the tissue, the retinas
were incubated first in 2.28% sodium m-periodate (Sigma,
St. Louis, MO, USA) in PB (5 minutes, RT) and then in
0.02% sodium borohydride (Panreac, Barcelona, Spain) in
PB (5 minutes, RT). After a blocking step (10% normal
goat serum in PB plus 0.5% triton X-100 for 1 hour), ret-
inas were incubated for 3 days at 4°C under agitation with
the primary antibody: mouse anti-rat integrin alpha M
(CD11b) clone OX-42 (1:500; Chemicon, Temeluca, CA,
USA), Retinas were washed 4 times in PB (5 minutes, RT)
and then incubated for 1 day at 4°C in biotinylated goat
anti-rabbit secondary IgG antibody at 1:100 dilution in PB
plus 0.5% triton X-100. The retinas were washed be-
fore transferring to a solution of avidin-biotin-peroxidase
complex (ABC) (Elite ABC kit, Vector Laboratories Ltd,
Cambridgeshire, UK) in PB containing 0.5% triton X-100
for 1 day. Finally, the retinas were washed in PB and pre-
incubated under agitation in the dark with 3,3′-diamino-
benzidine tetrahydrochloride (DAB, Sigma, St. Louis, MO,
USA; 0.5 mg/ml in PB) for 15 minutes and further incu-
bated with fresh DAB solution with 0.033% H2O2 and
0.025% ammonium nickel (II) sulfate hexahydrate (Sigma,
St. Louis, MO, USA). Washing with distilled water stopped
the DAB reaction. Whole retinas were flat-mounted in
Citifluor (Citifluor Ltd; London, UK) with the ganglion
layer side up, and coverslipped for optical microscopy
viewing on a Leica DMR microscope (Leica Microsystems,
Wetzlar, Germany).
For immunofluorescence imaging, vertical sections
were made. Eyecups were embedded in Tissue-Tek OCT
(Sakura Finetek, Zoeterwouden, Netherlands) and frozen
in liquid N2. Sixteen-micrometer-thick sections were
obtained at −25°C, mounted on slides (Superfrost Plus;Menzel GmbH and Co. KG, Braunschweig, Germany) and
air-dried. Before further use, slides were thawed and
washed 3 times in PB and treated with blocking solution
(10% donkey serum, 0.5% triton X-100 in PB) for 1 hour.
Sections were subjected overnight at room temperature
to single or double immunostaining with the primary
antibodies: polyclonal rabbit anti-ionized calcium-binding
adapter molecule 1 (Iba1, 1:1,000; Wako Chemicals,
Richmond, VA, USA) and mouse anti-major histocom-
patibility complex (MHC) class II RT1B clone OX-6
(1:200, AbD Serotec, Kidlington, UK), diluted in PB plus
0.5% triton X-100. The secondary antibodies used were
donkey anti-mouse or anti-rabbit IgG conjugated to Alexa
Fluor 488 or 555 (Molecular Probes, Eugene, OR, USA)
at a 1:100 dilution. Images were finally obtained under
a Leica (Wetzlar, Germany) TCS SP2 confocal laser-
scanning microscope. The spatial resolution employed
was 1,024 × 1,024, the pinhole was set at 1 airy units (AU)
and Z stacks were made with 15 pictures (1.5 μm steps).
All stacks were collected using a x40 objective and the
acquisition rate was 16 frames per second. Final images
from SD and P23H groups were processed in parallel
using Adobe Photoshop 10 software (Adobe Systems
Inc., San Jose, CA, USA). A subset of vertical sections
was stained by immunoperoxidase labeling.
Analysis of microglia cell number and morphology
Morphology, spatial distribution and mean number of
microglial cells were analyzed in the inner and outer plexi-
form layers (IPL, OPL), the ganglion cell layer (GCL) and
the subretinal space (SS) of whole-mount retinas. Macro-
phages detected in the GCL during the analysis were also
accounted. Four to six retinas from each animal group
(TUDCA-treated, untreated and SD animals) were exam-
ined. In each retina, 12 representative regions of 0.227 mm2
each were analyzed, 6 regions equidistantly arranged on the
superior-inferior axis of the retina and 6 fields disposed on
the temporal-nasal axis; thus sampling representative per-
ipheral, medial and central areas of the superior, inferior,
temporal and nasal quadrants of each retina. In each of the
12 regions analyzed in each retina, every one of the cell
bodies labeled with immunoperoxidase in each of the 3
layers analyzed was manually traced using a camera
lucida attached to the Leica DMR microscope (Leica
Microsystems, Wetzlar, Germany). Each retinal layer was
determined according to the vascular stratification of the
retinal tissue. The images created were subsequently digi-
tized using the image-editing software Photoshop (Adobe
Systems Inc., San Jose, CA, USA). The distribution pattern
of microglial cells in each retinal layer was assessed by
measuring the distances to the nearest neighbors of each
microglial cell using ImageJ software [39]. The distances
to the nearest neighbors were classified in histograms, sta-
tistically analyzed and compared with a nearest neighbor
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standard deviation [39,40]. For nearest neighbor distance
analysis we used images collected from the medial area of
the retina (superior quadrant).
To analyze microglial activation in each animal group,
we used cryostat vertical retinal sections immunostained
with Iba1 and MHC-II. We examined three vertical
sections non-consecutive per animal and we studied
six animals per experimental group. All the images
analyzed were collected from the central area of the
retina, close to the optic nerve. In every retinal sec-
tion, the total number of microglial cells expressing
one or both markers (Iba1+/MHC-II−, Iba1−/MHC-II+
and Iba1+/MHC-II+) was counted using light micros-
copy at x63 magnification. The obtained data were re-
ferred to the length of each retinal section, measured
using the ImageJ software.Statistical analysis
Statistical analyses were performed using the GraphPad
software from Prism (La Jolla, CA, USA), in order to
evaluate differences between SD, P23H untreated and
P23H TUDCA-treated rats. A one-way ANOVA was
used to evaluate differences in the mean number of
microglial cells, and a two-way ANOVA was performed
to compare the number of microglial cells corresponding
to each one of the three expression patterns analyzed
(Iba1+/MHC-II−, Iba1−/MHC-II+ and Iba1+/MHC-II+).
When a 0.05 level of significance was found, post hoc
pairwise comparisons using Bonferroni’s test were
performed. Normal distributions and homogeneity of
variance were found for all analyzed categories. Values
of P <0.05 were considered statistically significant. Data
were plotted as the average ± standard error of the
mean (SEM).Figure 1 Distribution and morphology of microglial cells in Sprague-D
immunolabeled with CD11b (OX-42). Note the presence of amoeboid CD1
subretinal space. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inn
Scale bar: 10 μm.Results
Distribution and morphology of retinal microglia in SD
and P23H rats
Microglial cells were identified by specific labeling with
CD11b, a constitutive marker of microglia and macro-
phages. In normal SD rat retinas, microglial cells were
distributed in a plexus located at the inner and outer
plexiform and ganglion cell layers (Figure 1A). Microglia
in SD retinas showed a tiny cell soma, little perinuclear
cytoplasm, and a large number of fine, branched processes
covered in numerous projections. In the ganglion cell
layer, few CD11b-positive cells with amoeboid morph-
ology were also found.
In the untreated P23H rat retina, an increase in micro-
glial cell number was found compared with control SD
rat retinas (Figure 1B). Moreover, numerous amoeboid
CD11b-positive cells were observed in all retinal layers,
with greater presence in IPL, OPL and the space that lies
between the photoreceptors and the RPE, the SS. The
most apparent morphologic features of amoeboid CD11b-
positive cells were scarce short and thick primary and ter-
minal processes and enlarged soma. In P23H rats treated
with TUDCA, amoeboid CD11b-positive cells were less
abundant than in untreated P23H rats in all layers of the
retina, with absence of microglial cells into the SS. Also,
the microglial morphology of P23H-treated group was
most closely related with SD control group than with
non-treated P23H group. Figure 2 shows a schematic
representation of the distribution and morphology of
microglial cells in SD, P23H-untreated and P23H TUDCA-
treated rats.
Figure 3 illustrates the presence of microglia into the SS
of untreated P23H rats (Figure 3B). Nearly all microglial
cells found in this stratum showed morphologic features
of amoeboid CD11b-positive cells. These microglial cells
probably reach the retina from the sclera and are notawley (SD) (A) and P23H (B) rats. Retinal vertical sections were
1b-positive cells in different layers of the P23H rat retina, including the
er nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer.
Figure 2 Drawing of the most representative morphology and location of microglial cells in Sprague-Dawley (SD) (A), untreated P23H
(B) and tauroursodeoxycholic acid (TUDCA)-treated P23H (C) rats. Note the absence of microglial cells into the subretinal space of P23H rats
treated with TUDCA. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear
layer; SS, subretinal space.
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tent not only in normal retinas of SD rats (Figure 3A), but
also in TUDCA-treated P23H rats (Figure 3C).
TUDCA reduces microglial cell number in P23H rats
To assess the effect of TUDCA on the density and distribu-
tion of retinal microglial cells in P23H rats, the relative
number of CD11b-positive cells was determined in the
GCL, IPL, OPL and SS of whole-mount retinas from SD (n
= 4), untreated P23H (n = 6) and TUDCA-treated P23H
rats (n = 6). Considering together all sampled areas, un-
treated P23H rats showed a relative number of immunopo-
sitive cells significantly greater compared to normal SD rats
(ANOVA, Bonferroni’s test, P <0.001; Figure 4A). These dif-
ferences were significant in the GCL, IPL, OPL and SS
(ANOVA, Bonferroni’s test, P <0.001 in all cases; Figure 4B).
TUDCA-treated P23H rats also showed a mean number of
microglial cells per mm2 significantly greater than SD rats
(ANOVA, Bonferroni’s test, P <0.01; Figure 4A), with sig-
nificant differences in the GCL, IPL and OPL (ANOVA,
Bonferroni’s test, P <0.05 in GCL and IPL, and P <0.001 in
OPL; Figure 4B). However, the mean number of CD11b-
positive cells was significantly lower in TUDCA-treated
P23H rats, as compared to untreated P23H rats (ANOVA,
Bonferroni’s test, P <0.001; Figure 4A), those differences
were statistically significant in the GCL, IPL, OPL and SS
(ANOVA, Bonferroni’s test, P <0.001 in all cases; Figure 4B).Figure 3 Migration of microglia into the subretinal space of untreate
tauroursodeoxycholic acid (TUDCA)-treated P23H (C) rat immunolabeled w
in the subretinal space of untreated P23H rats. Scale bar: 40 μm.No microglial cells were found in the SS of TUDCA-
treated P23H rats, as observed in normal SD rats.
Figure 5 shows representative drawings of the CD11b-
positive cells found in the medial area of the retina (su-
perior quadrant) of a SD, untreated P23H and TUDCA-
treated P23H rat, differentiating microglial cells located
in the GCL, IPL and OPL. According to data obtained in
the quantitative analysis shown in Figure 4, we can see
that TUDCA-treated P23H rat retinas (Figure 5C) had a
density of microglial cells intermediate between the one
found in SD rats (Figure 5A) and observed in untreated
P23H rats (Figure 5B), indicating a significant effect of
TUDCA reducing the relative number of microglial cells
in all retinal layers. Representative drawings in Figure 5
(A-C) also show that, regardless of the microglia density,
microglial cells are regularly distributed within each ret-
inal layer in SD, untreated P23H and TUDCA-treated
P23H rats. As we can see in Figure 5 (D-F) the distribu-
tion patterns of microglial cells in the GCL, IPL and
OPL, obtained by measuring the distances to the nearest
neighbors of each microglial cell, show a Gaussian form
and are symmetric around the mean (Figure 5D-F, solid
line). As we can see in the figure, these histograms can-
not be described by the nearest neighbors analysis of
random patterns of the same density and standard devi-
ation (Figure 5D-F, dotted line). It indicates that the dis-
tances to the nearest neighbors are uniform, and thatd P23H rats. Whole-mount retina of a SD (A), untreated P23H (B) and
ith CD11b (OX-42), showing the presence of amoeboid microglial cells
Figure 4 Quantification of retinal microglial cells. (A) Average number of positively stained microglial cells quantified in whole-mount retinas
from SD (n = 4; green), untreated P23H (n = 6; red) and tauroursodeoxycholic acid (TUDCA)-treated P23H rats (n = 6; grey). (B) Average number
of microglial cells in the GCL, IPL, OPL and SS of the retinas analyzed in (A). *P <0.05, **P <0.01, ***P <0.001; ANOVA, Bonferroni’s test.
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not distributed at random.
Regardless of the retinal layer in which they were
located, most of the microglia found in SD retinas showed
a tiny cell soma, little perinuclear cytoplasm, and a large
number of fine, branched processes covered in numerous
projections. CD11b-positive cells with amoeboid mor-
phology were scarce in SD rats. By contrast, numerous
amoeboid microglial cells, with scarce short and thick
primary and terminal processes and enlarged soma, were
observed in all retinal layers of untreated P23H rats. In
TUDCA-treated P23H rats, amoeboid CD11b-positive
cells were less abundant than in untreated P23H rats in all
layers of the retina. Distribution of microglial cells within
each retinal layer (GCL, IPL and OPL; Figures 6, 7 and 8,
respectively) was homogeneous in both SD and P23H rats.
No differences in microglial density were found between
the 12 regions analyzed in each retinal layer. This result
implies that the increase in the number of microglial cells
in P23H rats compared to SD rats (showed in Figure 4)
was analogous in all regions of the GCL, IPL and OPL
(Figures 6, 7 and 8, respectively). In TUDCA-treated P23H
rats, microglial cells were also homogeneously distributed
within the retinal layers, the density of microglial cells in
each region of the retina being in these animals lower than
that observed in untreated P23H rats.
TUDCA prevents activation of microglial cells in P23H rats
Microglial activation was assessed in SD, untreated
P23H and TUDCA-treated P23H rats by analyzing verti-
cal retinal sections immunostained with Iba1, a constitu-
tively expressed microglial specific marker, and MHC-II,
a marker that is frequently present on activated micro-
glia. The total number of microglial cells expressing
one or both markers was counted. As we can see in
Figure 9, MHC-II-negative cells labeled with anti-Iba1antibody (Iba1+/MHC-II−) had the typical appearance of
resting microglia, while MHC-II-positive cells showed
morphologic features of activated microglia; thus proving
that MHC-II expression is associated to microglial ac-
tivation. In SD rat retinas, all Iba1-positive cells found
showed morphologic features of resting microglia and were
not labeled by anti-MHC-II antibody (Iba1+/MHC-II−,
Figure 9A-C and Figure 10B). In the retinas of untreated
P23H rats, microglia density was significantly higher
than the one observed in the SD rats (183%; ANOVA,
Bonferroni’s test, P <0.001; Figure 9D-E and Figure 10A).
Moreover, a high proportion of microglial cells in un-
treated P23H rat retinas were MHC-II-positive (43%;
Figure 10B). Finally, a small group of MHC-II-positive
cells found in untreated P23H rat retinas was not labeled
by anti-Iba1 antibody (5%; Iba1−/MHC-II+; Figure 10B).
In TUDCA-treated P23H rats, microglia density was simi-
lar to the one observed in the SD rats (108%), and sig-
nificantly smaller than that found in untreated P23H rats
(59%; ANOVA, Bonferroni’s test, P <0.001; Figure 9G-I
and Figure 10A). The relative number of MHC-II-positive
cells not labeled by anti-Iba1 antibody in TUDCA-treated
P23H rats was also lower than in untreated P23H rats
(27.8%; Iba1−/MHC-II+; Figure 10B).
TUDCA reduces the presence of macrophages in the
P23H rats
Immunolabeling of whole-mount retinas with the micro-
glia/macrophages marker CD11b revealed the presence
of CD11b-positive cells with morphological characteris-
tics of macrophages in the central, medial and peripheral
areas of the GCL in SD, untreated P23H and TUDCA-
treated P23H rats (Figure 11). In untreated P23H rats,
the mean density of macrophages in the GCL was sig-
nificantly higher than in SD rats (ANOVA, Bonferroni’s
test, P <0.001; 23.6 ± 4.8 cells/mm2 versus 8.1 ± 1.0 cells/
Figure 5 Analysis of the distribution pattern of microglial cells. (A-C) Drawings of microglial cell bodies labeled with immunoperoxidase in a
representative area of the retina of a SD (A), untreated P23H (B) and tauroursodeoxycholic acid (TUDCA)-treated P23H rat (C). The localization of
microglial cells in each of the retinal layers studied has been specified: GCL, red; IPL, green; OPL, blue. All images were collected from the medial
area of the retina, in the superior quadrant. (D-F) Histograms of the nearest neighbors analysis in the OPL, IPL and GCL of SD (D), untreated P23H
(E) and TUDCA-treated P23H rats (F). The solid line indicates the Gaussian function fitted to the data. The nearest neighbors analysis of a random
pattern of the same density and standard deviation has been included for comparisons (dotted line). GCL, ganglion cell layer; IPL, inner plexiform
layer; OPL, outer plexiform layer. Scale bar: 500 μm.
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showed a mean density of macrophages in GCL (7.2 ±
1.4 cells/mm2) similar to the one observed in SD rats
and significantly lower than that found in untreated
P23H rats (ANOVA, Bonferroni’s test, P <0.001;
Figure 11).Discussion
The present study revealed that microglia are arranged
in regular mosaics homogeneously distributed within the
GCL, IPL and OPL in the normal rat retina and degen-
erative changes in the retina of P23H rats are associated
to significant increases in microglia density, as well as to
Figure 6 Morphology, number and distribution of microglial cells in the ganglion cell layer (GCL). (A-C) Representative images of whole-
mount rat retinas from a SD (A), untreated P23H (B) and tauroursodeoxycholic acid (TUDCA)-treated P23H rat (C) labeled with immunoperoxidase.
(E, G, I) Magnifications of (A), (B) and (C), respectively. (D, F, H) Drawings of microglial cells from SD (D), untreated P23H (F) and TUDCA-treated P23H
rat (H). (J, K) Microglial density, expressed as number of cells per mm2, in each of 12 representative regions in each retina: 6 equidistantly arranged on
the superior-inferior axis of the retina (J) and 6 disposed on the temporal-nasal axis (K). The scheme in the margin of each panel represents the position
in the retina of each representative region analyzed. (A, B, C) scale bar: 40 μm; (D, F, H) scale bar: 20 μm; (E, G, I) scale bar: 10 μm.
Noailles et al. Journal of Neuroinflammation 2014, 11:186 Page 8 of 15
http://www.jneuroinflammation.com/content/11/1/186the appearance of a large number of amoeboid CD11b-
positive cells, even into the SS. Previous studies have
already demonstrated the relation between microglial
activation and the progression of neurodegenerative dis-
eases, including RP [18]. However, to our knowledge,
this is the first time that changes in microglial cell num-
bers, distribution and morphology have been described
in the P23H rat, a rat model of autosomal dominant RP
characterized by a slow-pace retinal degeneration [40,41].
In this study, we also documented that systemic treatment
with the antiapoptotic TUDCA attenuates changes in
number, distribution and morphologic features of micro-
glial cells in P23H rats.We identified that in normal Sprague-Dawley rat retinas
CD11b-positive microglial cells were homogeneously dis-
tributed in the GCL, IPL and OPL; most of them showing
morphologic features of resting microglia, although few
CD11b-positive cells with amoeboid morphology were
found in the GCL. These results agree with previous stud-
ies in rats showing that as the layers of the retina differen-
tiate, microglial cells are increasingly restricted to the
inner half of the retina [42]. More, recent studies have
shown that OX42-immunoreactive microglial cells are
distributed mainly in the nerve fiber layer (NFL) and
GCL, with some cells localized in the IPL, but rarely in
the OPL [43]. On the other hand, previous studies have
Figure 7 Morphology, number and distribution of microglial cells in the inner plexiform layer (IPL). (A-C) Representative images of
whole-mount rat retinas from a SD (A), untreated P23H (B) and tauroursodeoxycholic acid (TUDCA)-treated P23H rat (C) labeled with
immunoperoxidase. (E, G, I) Magnifications of (A), (B) and (C), respectively. (D, F, H) Drawings of microglial cells from SD (D), untreated P23H (F)
and TUDCA-treated P23H rat (H). (J, K) Microglial density, expressed as number of cells per mm2, in each of 12 representative regions in each
retina: 6 equidistantly arranged on the superior-inferior axis of the retina (J) and 6 disposed on the temporal-nasal axis (K). The scheme in the
margin of each panel represents the position in the retina of each representative region analyzed. (A, B, C) scale bar: 40 μm; (D, F, H) scale bar:
20 μm; (E, G, I) scale bar: 10 μm.
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http://www.jneuroinflammation.com/content/11/1/186reported the presence of a network of macrophages in the
inner layers of the rat normal retina [44]. In agreement
with these previous findings, we found the presence of
CD11b-positive cells with morphological characteristics of
macrophages in the central, medial and peripheral areas
of the GCL in SD rats. The analysis of the distribution
pattern of microglial cells in each retinal layer showed that
microglial cells are arranged in a regular mosaic in both
SD and P23H rats. This result is in accordance with the
arrangement in a spatially regular manner of many types
of retinal neurons, including photoreceptors [45,46]. The
result also suggests the existence of mechanisms involvedin the development of regular cellular positioning within
each retinal layer.
In untreated P23H rat retinas, microglia density in-
creased in the GCL, IPL and OPL, microglial cells ap-
peared in the SS, and a large number of CD11b-positive
cells were labeled with anti-MHC-II, a marker of micro-
glial activation, and showed morphological features of
amoeboid cells. The mean density of macrophages in the
GCL was also higher in untreated P23H rats as com-
pared to SD rats. These results are in accordance with
changes in microglial cells number, activation and distri-
bution previously reported in different forms of disease
Figure 8 Morphology, number and distribution of microglial cells in the outer plexiform layer (OPL). (A-C) Representative images of
whole-mount rat retinas from a SD (A), untreated P23H (B) and tauroursodeoxycholic acid (TUDCA)-treated P23H rat (C) labeled with
immunoperoxidase. (E, G, I) Magnifications of (A), (B) and (C), respectively. (D, F, H) Drawings of microglial cells from SD (D), untreated P23H (F)
and TUDCA-treated P23H rat (H). (J, K) Microglial density, expressed as number of cells per mm2, in each of 12 representative regions in each
retina: 6 equidistantly arranged on the superior-inferior axis of the retina (J) and 6 disposed on the temporal-nasal axis (K). The scheme in the
margin of each panel represents the position in the retina of each representative region analyzed. (A, B, C) Scale bar: 40 μm; (D, F, H) scale bar:
20 μm; (E, G, I) scale bar: 10 μm.
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macular degeneration [20,48], light damage [49,50] and
RP [18]. In the mouse model of RP rd10, high levels of
pro-inflammatory cytokines and chemokines and early
microglial activation have been demonstrated [51,52].
Previous studies have also demonstrated increased density
of macrophages after microglial activation [44]. Here we
showed that CD11b-positive microglial cells were homo-
geneously distributed within each of the retinal layers in
P23H rats. Nonetheless, retinal degeneration in P23H rats
was not homogeneous throughout the retina. Previous
studies have reported more advanced stages ofdegeneration in the medial retina compared with the cen-
tral and peripheral retina [34,53]. This result evidences
that there is no correlation between the state of degener-
ation in different areas of the retina and glial activation in
the same region. The result also suggests that the signals
that mediate activation of microglia either do not depend
on the state of degeneration of the retina, or are homoge-
neously distributed within each retinal layer.
Microglial cells have been reported to exhibit the ex-
pression of the ionized calcium-binding adaptor molecule
1 (Iba1), a microglia/macrophage-specific calcium-binding
protein found in all microglial populations [54-57]. This
Figure 9 Activation of microglial cells. Vertical section of retinas from a SD (A-C), untreated P23H (D-F) and tauroursodeoxycholic acid
(TUDCA)-treated P23H (G-I) rat stained for Iba1 (green; A, D, G) MHC-II RT 1B (red; B, E, H) or both (C, F, I). Nuclei stained with a nuclear marker
(TO-PRO 3, blue). All images were collected from the central area of the retina, close to the optic nerve. GCL, ganglion cell layer; IPL, inner
plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bar: 20 μm.
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http://www.jneuroinflammation.com/content/11/1/186protein is involved in the membrane ruffling processes of
macrophages/microglia so it is considered one of the most
important molecules in the motile properties of these cells
[54]. In our study, a small group of MHC-II-positive cells
was not labeled by anti-Iba1 antibody in P23H rat retinas.
This finding can be explained by assuming that microglial
cells may have different expression pattern according to
their provenance. Perhaps, Iba1− cells are migrating mi-
croglia that attend to the retinal tissue in response to a
chronic negative insult. Another explanation of the pres-
ence of Iba1− microglial cells could be that these cells are
defective or senescent microglial cells that have lost their
migrating capacities and down-regulated the Iba1 expres-
sion. Possibly, the appearance of this novel expression pat-
tern responds to a different stage of microglial cells within
the microglial activation process, wherein each of the
stages is characterized by a common expression pattern.
TUDCA in P23H rats reduced the number and activa-
tion of microglial cells and macrophages. Moreover, in
TUDCA-treated rat retinas microglia were mainly distrib-
uted in more internal retinal layers, GCL and IPL, andthey were scarce in the OPL and missing in the SS, which
is similar to that found in normal SD rat retinas. This
result suggests that TUDCA effects on retinal microglia
could be due, at least in part, to a reduction in the
microglial migratory capacity. Attenuation of microglial
activation using TUDCA has been previously demon-
strated in experimental models of neuroinflammation,
in which it has been reported that TUDCA reduces
in vitro microglial migration and the expression of che-
moattractants required for microglial migration [58].
The effects of TUDCA on retinal microglial cells could be
also attributed to an effect of TUDCA on microglial cells
behavior, presumably interfering in the respiratory burst
of the microglia, which is a critical step in its activa-
tion [59,60]. Besides its direct action on microglial cells,
TUDCA could act on an indirect way. Through its anti-
apoptotic properties, TUDCA slows apoptosis of the
retinal tissue [34].
Microglial cells in the retina act as sensors of disar-
rangement in their micro-environment. Their balanced
activities play a key role in the survival of neurons [6,30].
Figure 10 Quantification of retinal microglial activation. (A) Average number of Iba1 and/or MHC-II positive microglial cells quantified in
vertical retinal sections from SD, untreated P23H and tauroursodeoxycholic acid (TUDCA)-treated P23H rats (6 animals per group). (B) Average
number of microglial cells showing the expression patterns Iba1+/MHC-II− (green), Iba1−/MHC-II+ (red) and Iba1+/MHC-II+ (yellow). ***P <0.001;
ANOVA, Bonferroni’s test.
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http://www.jneuroinflammation.com/content/11/1/186Activation of the microglia has been demonstrated in
association with several neurodegenerative diseases, such
as Alzheimer’s and Parkinson’s diseases, amyotrophic lat-
eral sclerosis, and multiple sclerosis, although it remains
unclear whether microglial activation is a cause or aFigure 11 Number and distribution of macrophages in the ganglion c
retinas from a SD (A), untreated P23H (B) and tauroursodeoxycholic acid (T
Density of macrophages, expressed as number of cells per mm2, in each o
the superior-inferior axis of the retina (D) and 6 disposed on the temporal-
position in the retina of each representative region analyzed. Scale bar: 40consequence of neuronal damage [17,61]. The true role of
microglia in neurodegenerative diseases, as either a bene-
ficial or harmful factor, still remains controversial, and a
large body of results has been obtained to support both
hypotheses. Activated microglial cells have been shown toell layer (GCL). (A-C) Representative images of whole-mount rat
UDCA)-treated P23H rat (C) labeled with immunoperoxidase. (D, E)
f 12 representative regions in each retina: 6 equidistantly arranged on
nasal axis (E). The scheme in the margin of each panel represents the
μm.
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[62,63], and inhibition of microglial activation reduced
photoreceptor apoptosis and significantly improved retinal
structure and function [51,64]. In the rd10 mouse model
of RP, it has been demonstrated that reductions in the
amount of pro-inflammatory cytokines and chemokines
by antioxidant treatment inhibits microglial activation and
slows the photoreceptor loss [52]. Moreover, it has been
demonstrated that microglia are required for the neuro-
protective effect of insulin-like growth factor (IGF)-I in
the rd10 mouse retina [65]. Hence, the selective inhibition
of overacting microglial activity and preservation of their
trophic and homeostatic functions appear to be a promis-
ing treatment for degenerative diseases [30]. However, it
must also be noted that reactive microglial cells can also
have a protective effect in damaged retina and that the in-
hibition of microglial activation can have harmful effects
at the same time. In the early stages of the neurodegenera-
tive process, microglial activation can display a protective
function through the phagocytosis of cell debris and the
release of protective molecules [7,8,17]. In this sense, ac-
cumulation of microglia in ischemic areas correlates with
a reduction of neuronal damage and confers neuroprotec-
tion [66].
Conclusion
These experiments demonstrate that in normal and dis-
ease conditions microglial cells exhibit a mosaic distri-
bution throughout the retinal tissue, independently of
the state of degeneration. The data obtained in our work
also prove that microglial activation is actively involved
in the progression of RP. Moreover, we documented that
TUDCA reduces the number and activation of micro-
glial cells in a model of RP (P23H). These results report
novel TUDCA anti-inflammatory actions, with potential
therapeutic implications for neurodegenerative diseases,
including RP. Further studies are required to evaluate
the beneficial and/or harmful impact of these effects on
retinal structure and function.
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